BRAINSTORM CELL THERAPEUTICS(NASDAQ:BCLI) stock Analyst Ratings

Buy % Consensus

ChartMill assigns a Buy % Consensus number of 83% to BCLI. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 15.47. This target is 1222.51% above the current price.

BCLI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BCLI.

In the previous month the buy percentage consensus was at a similar level.

BCLI was analyzed by 7 analysts. More opinions would make the average more meaningful.

Price

Low

Median

Mean

High

1.17

6.06

17.34

15.47

23.64

417.95%

1,382.05%

1,222.51%

1,920.13%

Up and Down Grades

Date	Firm	Action	Rating
2025-07-23	Maxim Group	Downgrade	Buy -> Hold
2024-07-11	Maxim Group	Upgrade	Hold -> Buy
2023-09-28	Maxim Group	Downgrade	Buy -> Hold
2023-03-31	Maxim Group	Maintains	Buy

BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Analyst Ratings